Does the media favor CNTX or DTIL?

In the previous week, Precision BioSciences had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.55 beat Precision BioSciences' score of 0.28 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TNXP or CNTX?

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.55 beat Tonix Pharmaceuticals' score of -0.47 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CNTX or CGEN?

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Compugen's average media sentiment score of 0.75 beat Context Therapeutics' score of 0.55 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CNTX or ADAG?

Adagene has higher revenue and earnings than Context Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Adagene $7.67M 27.62 -$17.61M N/A N/A

Is CNTX or ADAG more profitable?

Adagene's return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Adagene N/A N/A N/A

Does the media prefer CNTX or ADAG?

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.55 beat Adagene's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NKTX or CNTX?

Nkarta is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Context Therapeutics N/A N/A -$36.12M -$0.42 N/A

Is NKTX or CNTX more profitable?

Nkarta's return on equity of -30.90% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Context Therapeutics N/A -59.95% -54.78%

Context Therapeutics (CNTX) Competitors

$0.65 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.65 0.00 (-0.11%)

As of 07/2/2026 07:57 PM Eastern

Compare

CNTX vs. DTIL, TNXP, CGEN, ADAG, and NKTX

Should you buy Context Therapeutics stock or one of its competitors? MarketBeat compares Context Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Context Therapeutics include Precision BioSciences (DTIL), Tonix Pharmaceuticals (TNXP), Compugen (CGEN), Adagene (ADAG), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

How does Context Therapeutics compare to Precision BioSciences?

Context Therapeutics (NASDAQ:CNTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Context Therapeutics currently has a consensus price target of $6.17, suggesting a potential upside of 843.35%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 294.25%. Given Context Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Context Therapeutics is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Precision BioSciences had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.55 beat Precision BioSciences' score of 0.28 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Context Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Context Therapeutics' return on equity of -59.95% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Context Therapeutics has higher earnings, but lower revenue than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Precision BioSciences	$34.26M	6.16	-$45.72M	-$3.67	N/A

Summary

Context Therapeutics beats Precision BioSciences on 12 of the 16 factors compared between the two stocks.

How does Context Therapeutics compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Tonix Pharmaceuticals has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 1 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.55 beat Tonix Pharmaceuticals' score of -0.47 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Context Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	15.00	-$124.02M	-$14.36	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Context Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Context Therapeutics' return on equity of -59.95% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Context Therapeutics	N/A	-59.95%	-54.78%

Tonix Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 94.49%. Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 843.35%. Given Context Therapeutics' higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Context Therapeutics beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Context Therapeutics compare to Compugen?

Context Therapeutics (NASDAQ:CNTX) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Compugen's average media sentiment score of 0.75 beat Context Therapeutics' score of 0.55 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 843.35%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 119.30%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has a net margin of 47.97% compared to Context Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Compugen	47.97%	47.72%	27.51%

Compugen has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

Summary

Compugen beats Context Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Adagene?

Context Therapeutics (NASDAQ:CNTX) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Adagene's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Adagene	N/A	N/A	N/A

Adagene has higher revenue and earnings than Context Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Adagene	$7.67M	27.62	-$17.61M	N/A	N/A

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 843.35%. Adagene has a consensus target price of $8.00, suggesting a potential upside of 78.97%. Given Context Therapeutics' higher possible upside, equities analysts plainly believe Context Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Adagene has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.55 beat Adagene's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adagene beats Context Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Context Therapeutics compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Nkarta has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 233.85%. Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 843.35%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Context Therapeutics had 1 more articles in the media than Nkarta. MarketBeat recorded 1 mentions for Context Therapeutics and 0 mentions for Nkarta. Context Therapeutics' average media sentiment score of 0.55 beat Nkarta's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nkarta	Neutral
Context Therapeutics	Positive

Nkarta is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

80.5% of Nkarta shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nkarta's return on equity of -30.90% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Context Therapeutics	N/A	-59.95%	-54.78%

Summary

Context Therapeutics beats Nkarta on 9 of the 13 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.06M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-1.56	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.99	4.32	10.96	6.46
Net Income	-$36.12M	$64.45M	$3.57B	$337.01M
7 Day Performance	12.71%	2.97%	2.12%	1.69%
1 Month Performance	-62.65%	6.83%	5.25%	3.81%
1 Year Performance	-0.20%	29.07%	33.29%	23.90%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	3.4397 of 5 stars	$0.65 flat	$6.17 +843.3%	-0.2%	$60.06M	N/A	N/A	7	Gap Down
DTIL Precision BioSciences	2.5477 of 5 stars	$7.96 +0.5%	$32.25 +305.2%	+87.0%	$205.34M	$34.26M	N/A	200	News Coverage
TNXP Tonix Pharmaceuticals	3.9156 of 5 stars	$12.85 +0.8%	$24.00 +86.8%	-65.2%	$204.83M	$13.11M	N/A	50	Gap Up
CGEN Compugen	3.7975 of 5 stars	$2.17 +0.2%	$5.00 +130.9%	+28.1%	$204.71M	$72.66M	5.85	70	Gap Down
ADAG Adagene	1.8294 of 5 stars	$4.27 +0.8%	$8.00 +87.6%	+137.1%	$202.10M	$7.67M	N/A	260	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. DTIL, TNXP, CGEN, ADAG, and NKTX

How does Context Therapeutics compare to Precision BioSciences?

Summary

How does Context Therapeutics compare to Tonix Pharmaceuticals?

Summary

How does Context Therapeutics compare to Compugen?

Summary

How does Context Therapeutics compare to Adagene?

Summary

How does Context Therapeutics compare to Nkarta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. DTIL, TNXP, CGEN, ADAG, and NKTX

How does Context Therapeutics compare to Precision BioSciences?

Do analysts rate CNTX or DTIL?

Does the media favor CNTX or DTIL?

Which has more risk & volatility, CNTX or DTIL?

Do insiders & institutionals have more ownership in CNTX or DTIL?

Is CNTX or DTIL more profitable?

Which has better earnings and valuation, CNTX or DTIL?

Summary

How does Context Therapeutics compare to Tonix Pharmaceuticals?

Which has more volatility & risk, TNXP or CNTX?

Does the media favor TNXP or CNTX?

Which has better earnings and valuation, TNXP or CNTX?

Is TNXP or CNTX more profitable?

Do analysts prefer TNXP or CNTX?

Do institutionals & insiders believe in TNXP or CNTX?

Summary

How does Context Therapeutics compare to Compugen?

Does the media prefer CNTX or CGEN?

Do analysts prefer CNTX or CGEN?

Is CNTX or CGEN more profitable?

Which has better valuation and earnings, CNTX or CGEN?

Do institutionals and insiders hold more shares of CNTX or CGEN?

Which has more risk and volatility, CNTX or CGEN?

Summary

How does Context Therapeutics compare to Adagene?

Is CNTX or ADAG more profitable?

Which has higher earnings & valuation, CNTX or ADAG?

Do institutionals & insiders hold more shares of CNTX or ADAG?

Do analysts rate CNTX or ADAG?

Which has more risk & volatility, CNTX or ADAG?

Does the media prefer CNTX or ADAG?

Summary

How does Context Therapeutics compare to Nkarta?

Which has more volatility and risk, NKTX or CNTX?

Do analysts recommend NKTX or CNTX?

Does the media favor NKTX or CNTX?

Which has stronger valuation and earnings, NKTX or CNTX?

Do insiders & institutionals believe in NKTX or CNTX?

Is NKTX or CNTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools